sur Theranexus (EPA:ALTHX)
Theranexus Publishes its Letter to Shareholders
The biopharmaceutical company Theranexus, which specializes in the treatment of rare neurological diseases, announced the publication of its letter to shareholders on January 9, 2025. This document is available on the company's website in the Shareholders section.
Theranexus encourages its shareholders to subscribe to receive its communications. The company, which emerged from the CEA, stands out with an innovative platform dedicated to drug candidates for rare neurological disorders. Its first clinical project concerns Batten disease.
However, Theranexus highlights limited financial outlook through the first quarter of 2026, which could result in significant dilution for its shareholders. Economic and market fluctuations add to current uncertainties.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Theranexus